Complete atrial ventricular block in a patient treated with transcutaneous rivastigmine
DOI:
https://doi.org/10.32818/reccmi.a6n2a13Keywords:
rivastigmine, atrial ventricular block, adverse effects.Abstract
The use of drugs with the potential of causing multiple side effects and interactions is very common among our ageing and polymedicated population. Rivastigmine, used for dementia, can produce various adverse reactions, including severe cardiac arrhythmias due to reduced acetylcholine metabolism. These can be antagonized with atropine but sometimes pacemaker implantation may become necessary due to the long duration of the drug's effect. Therefore, before prescribing acetylcholine inhibitors, it is essential to rule out pre-existing cardiac conduction disorders in the patient and, in the event of any rhythm or cardiac conduction disorders, perform an electrocardiogram, and assess the risk/benefit of the treatment.
Downloads
Metrics
References
- Hernández-Rodríguez MÁ, Sempere-Verdú E, Vicens-Caldentey C, González-Rubio F, Miguel-García F, Palop-Larrea V et al. Drug Prescription Profiles in Patients with Polypharmacy in Spain: A Large-Scale Pharmacoepidemiologic Study Using Real-World Data. Int J Environ Res Public Health. 2021; 18(9): 4754. doi: https://doi.org/10.3390/ijerph18094754.
- Agencia Española de Medicamentos y Productos Sanitarios. CIMA [On line]. Accesible en: https://cima.aemps.es/cima/publico/buscadoravanzado.html. Último acceso 17 de febrero de 2021.
- Pink J, O´Brien J, Robinson L, Longson D. Dementia: Assessment, management and support: summary of updated NICE guidance. BMJ. 2018; 361: k2438. doi: https://doi.org/10.1136/bmj.k2438.
- Malone K, Hancox JC. QT interval prolongation and Torsades de Pointes with donepezil, rivastigmine and galantamine. Ther Adv Drug Saf. 2020; 11: 2042098620942416. doi: https://doi.org/10.1177/2042098620942416.
-. Alonge O, Iqbal FM, Cifonelli E. Collapse in the elderly: rivastigmine-induced heart block and a literature review of the pharmacology of acetylcholinesterase inhibitors used in Alzheimer's disease. BMJ Case Rep. 2018; 2018: bcr2018224597. doi: https://doi.org/10.1136/bcr-2018-224597.
- Walsh E, Dourish J. Prolonged QT interval with rivastigmine. Br J Psychiatry. 2002; 180: 466. doi: https://doi.org/10.1192/bjp.180.5.466-a.
- Juanena C, Pose D, Sosa G, Pose F, Balzani M, Senattore V. Toxicidad cardiovascular por parches transdérmicos de rivastigmina. A propósito de dos casos clínicos. Rev Urug Cardiol 2019; 34:296-300. Accesible en: https://www.suc.org.uy/revista/v34n3/pdf/rcv34n3_15.pdf. Último acceso julio 2021.
- Isik AT, Ates Bulut E, Dokuzlar O, Kaya D, Erken N, Dost Gunay FS et al. Cardiac and Blood Pressure Safety of Transdermal Rivastigmine in Elderly Patients With Dementia With Lewy Bodies. Alzheimer Dis Assoc Disord. 2020; 34(4): 339-343. doi: https://doi.org/10.1097/WAD.0000000000000401.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Julia Carranza Urones, Ana Isabel Grocin Vidaondo, Vanessa Vals Casulá, Maia Bernad Barcos, Ion Koldobika Iribar Diéguez
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Permite compartir, copiar y redistribuir el material en cualquier medio o formato, bajo los siguientes términos:
Reconocimiento: debe otorgar el crédito correspondiente, proporcionar un enlace a la licencia e indicar si se realizaron cambios. Puede hacerlo de cualquier manera razonable, pero no de ninguna manera que sugiera que el licenciante lo respalda a usted o su uso.
No comercial: no puede utilizar el material con fines comerciales.
No Derivados: si remezcla, transforma o construye sobre el material, no puede distribuir el material modificado.
Sin restricciones adicionales: no puede aplicar términos legales o medidas tecnológicas que restrinjan legalmente a otros de hacer cualquier cosa que permita la licencia.
